Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 153Neoplasm Metastasis 145Neoplasms 142Breast Neoplasms 142Colorectal Neoplasms 135Recurrence 105Ovarian Neoplasms 100Pancreatic Neoplasms 81Multiple Myeloma 81Lung Neoplasms 81Advanced Solid Tumor 80Advanced Solid Tumors 74Prostatic Neoplasms 73Stomach Neoplasms 72Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 67Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 63Triple Negative Breast Neoplasms 57Myelodysplastic Syndromes 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 53Lymphoma, B-Cell 53Endometrial Neoplasms 52Glioma 51Lymphoma 49Brain Neoplasms 46Hematologic Neoplasms 44Carcinoma, Renal Cell 44

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Congenital Bone Marrow Failure Syndromes × Clear all
NCT06090669 2026-06-03

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
75 enrolled
Classical hematology

Congenital Bone Marrow Failure Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡